This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00907517
First received: May 21, 2009
Last updated: November 30, 2016
Last verified: November 2016
May 21, 2009
November 30, 2016
July 2009
June 2011   (Final data collection date for primary outcome measure)
  • Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) [ Time Frame: Throughout Cycle 1 (Up to 6 weeks) ]
    Toxicity was assessed according to the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v 3.0). DLTs in Cycle 1 consisted of any of the following: 1) Selected Grade 4 drug-related nonhematologic toxicities, 2) Selected Grade 3 drug-related nonhematologic toxicities that do not resolve to ≤ Grade 2 within 48 hours: Neurotoxicity of any duration, Nephrotoxicity of any duration, QT interval corrected by Fridericia (QTcF) prolongation of any duration, 3) Inability to administer Day 10 cytarabine therapy due to ongoing, uncontrolled serious or life-threatening toxicity. The number of participants who experienced a DLT during Cycle 1 is summarized.
  • Number of Participants Who Experienced an Adverse Event (AE) [ Time Frame: Up to 45 days after last dose of study treatment (Up to 180 days) ]
    An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to this study treatment. The number of participants who experienced an AE is summarized.
  • Number of Participants Who Discontinued Study Treatment Due to an AE [ Time Frame: Up to 135 days ]
    An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to this study treatment. The number of participants who discontinued study treatment due to an AE is summarized.
Dose-limiting toxicities and biologic activity used to determine the recommended Phase 2 combination doses of SCH 900776 and cytarabine [ Time Frame: Throughout treatment ]
Complete list of historical versions of study NCT00907517 on ClinicalTrials.gov Archive Site
Not Provided
Description of the overall adverse event profile, including any dose-limiting toxicity, of SCH 900776 given alone and in combination with cytarabine [ Time Frame: Throughout treatment up to 45 days after last dose of study medication. ]
Not Provided
Not Provided
 
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
A Phase 1 Dose-Escalation Study of SCH 900776 in Combination With Cytarabine in Subjects With Acute Leukemias (Protocol No. P05247)
This study of SCH 900776 (MK-8776) will evaluate its safety and tolerability when given in combination with cytarabine to participants with acute leukemias. Participants in the Dose-Escalation Part will be enrolled in cohorts that will receive sequentially higher doses of MK-8776 in combination with standard doses of cytarabine. Only one combination treatment cycle of approximately 4 to 6 weeks is anticipated, but participants may receive additional cycles if clinically indicated after discussion between the Investigator and the Sponsor. The recommended combination doses for a Phase 2 trial (RP2D) will be determined based on safety and biological activity. Up to 10 to 15 additional participants will be studied at the combination RP2D.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Myelogenous Leukemia, Acute
  • Leukemia, Lymphocytic, Acute
  • Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
  • Myelogenous Leukemia, Chronic, Aggressive Phase
  • Drug: MK-8776
    IV infusion
    Other Name: SCH 900776
  • Drug: Cytarabine
    IV infusion
    Other Names:
    • Generic: ara-C and cytosine arabinoside
    • Cytosar-U®
  • Experimental: MK-8776 10 mg/m^2 + Cytarabine 2 g/m^2
    Participants received MK-8776 10 mg/m^2 intravenously (IV) on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour continuous intravenous infusion (CIV) on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
    Interventions:
    • Drug: MK-8776
    • Drug: Cytarabine
  • Experimental: MK-8776 20 mg/m^2 + Cytarabine 2 g/m^2
    Participants received MK-8776 20 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
    Interventions:
    • Drug: MK-8776
    • Drug: Cytarabine
  • Experimental: MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2
    Participants received MK-8776 40 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
    Interventions:
    • Drug: MK-8776
    • Drug: Cytarabine
  • Experimental: MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2
    Participants received MK-8776 56 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
    Interventions:
    • Drug: MK-8776
    • Drug: Cytarabine
  • Experimental: MK-8776 140 mg + Cytarabine 2 g/m^2
    Participants received MK-8776 140 mg flat dose IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
    Interventions:
    • Drug: MK-8776
    • Drug: Cytarabine
Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012 Dec 15;18(24):6723-31. doi: 10.1158/1078-0432.CCR-12-2442. Epub 2012 Oct 23.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
24
June 2011
June 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must have a histologically or cytologically confirmed diagnosis of relapsed and/or refractory acute leukemia, including:

    • acute myelogenous leukemia (AML), including AML arising from myelodysplasia (MDS) or myeloproliferative disorder (MPD);
    • acute lymphocytic leukemia, including Philadelphia chromosome-positive (Ph+) ALL (Dose-Escalation Part only);
    • chronic myelogenous leukemia (CML) in accelerated phase (AP) or blast crisis (BC) of either myeloid or lymphoid origin (Dose-Escalation Part only);
    • treatment-related high-grade MDS (i.e. refractory anemia with excess blasts in transformation [RAEBT]);
    • MPD in transformation [eg, CMMoL-T (5%-19% blasts)].
  • Must have recurred or progressed following standard therapy or failed standard therapy, or have disease for which no standard therapy currently exists.
  • Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
  • Females of childbearing potential must have a negative pregnancy test within 5 days prior to first dose of cytarabine.
  • Females of childbearing potential and males whose sexual partner is of childbearing potential must agree to abstain from sexual intercourse or to use an acceptable method of contraception during the study and for 90 days following the last dose of study treatment.
  • Must have adequate renal function as evidenced by a serum creatinine level <=1.5 x upper limit of normal (ULN) or a calculated creatinine clearance >=60 mL/min.
  • Participants, except ones with known Gilbert's Syndrome, must have adequate hepatic function as evidenced by a serum bilirubin level <=1.5 mg/dL AND serum levels of aspartate and alanine aminotransferase (AST/ALT) <=5 x the ULN for the reference laboratory.
  • Must have adequate cardiac function with a left ventricular ejection fraction (LVEF) of >=45% (echocardiogram or multiple-gated acquisition [MUGA] scan).
  • Must be recovered from the effects of any prior surgery, radiotherapy, or systemic antineoplastic therapy.
  • Participants who are refractory to or relapsed after prior allogeneic or autologous stem cell transplant are eligible.

Exclusion Criteria:

  • Must not have known hypersensitivity to MK-8776 or cytarabine or to any of their excipients or have received therapy with another Checkpoint kinase 1 (CHK1) inhibitor.
  • Must not have persistent, unresolved Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v 3.0) ≥ Grade 2 drug-related toxicity (except alopecia, erectile impotence, hot flashes, decreased libido, hematologic toxicity) associated with previous treatment.
  • Must not have known human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or have a known history of liver cirrhosis or active alcohol abuse.
  • Must not be New York Heart Association (NYHA) Class III (has marked limitation in activity due to symptoms, even during less than ordinary activity [e.g. walking short distances >20-100 m]; is comfortable only at rest) or Class IV (has severe limitations; experiences symptoms even while at rest; mostly bed bound).
  • Must not have undergone major surgery within 3 weeks prior to first study drug administration after enrollment.
  • Must not have known active central nervous system (CNS) or leptomeningeal leukemia.
  • Must not have received radiation therapy within 2 weeks prior to first study treatment administration after enrollment or radiation therapy to >25% of bone marrow.
  • Must not have received more than 4 prior induction regimens.
  • Must not have a peripheral blast count ≥50,000/mm^3.
  • Must not have active, uncontrolled graft versus host disease (GVHD) post-allogeneic stem cell transplant.
  • Must not have had any of the following within 6 months prior to first study treatment administration after enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or seizure disorder.
  • Must not have a known bleeding diathesis, e.g. hemophilia, or disseminated intravascular coagulation.
  • Must not have an active, uncontrolled infection.
  • Must not have a history of cytarabine-related neurotoxicity.
  • Must not have a baseline corrected QT (QTc) interval >470 msec (i.e. CTCAE v 3.0 Grade ≥2).
  • Must not currently be a smoker and/or must not be likely to smoke during the study.
  • Females must not be breast-feeding, pregnant, or intend to become pregnant.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00907517
P05247
MK-8776-001 ( Other Identifier: Merck Protocol Number )
No
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Director Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP